Cnp-38: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cnp-38. Educational only — not medical advice.
Labeled uses
YUVIWEL® is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Source: FDA labeling via NIH DailyMed (set e01c1197…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.